DK175372B1 - 1,3-dioxolanderivater - Google Patents

1,3-dioxolanderivater Download PDF

Info

Publication number
DK175372B1
DK175372B1 DK198901720A DK172089A DK175372B1 DK 175372 B1 DK175372 B1 DK 175372B1 DK 198901720 A DK198901720 A DK 198901720A DK 172089 A DK172089 A DK 172089A DK 175372 B1 DK175372 B1 DK 175372B1
Authority
DK
Denmark
Prior art keywords
dioxolane
compound according
trans
cis
isomers
Prior art date
Application number
DK198901720A
Other languages
Danish (da)
English (en)
Other versions
DK172089D0 (da
DK172089A (da
Inventor
Bernard Belleau
Dilip Dixit
Nghe Nhuyen-Ba
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22657287&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK175372(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Publication of DK172089D0 publication Critical patent/DK172089D0/da
Publication of DK172089A publication Critical patent/DK172089A/da
Priority to DK200200474A priority Critical patent/DK200200474A/da
Application granted granted Critical
Publication of DK175372B1 publication Critical patent/DK175372B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Secondary Cells (AREA)
  • Peptides Or Proteins (AREA)
  • Paints Or Removers (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
DK198901720A 1988-04-11 1989-04-10 1,3-dioxolanderivater DK175372B1 (da)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK200200474A DK200200474A (da) 1988-04-11 2002-03-27 1,3-dioxolanderivater

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17961588A 1988-04-11 1988-04-11
US17961588 1988-04-11

Publications (3)

Publication Number Publication Date
DK172089D0 DK172089D0 (da) 1989-04-10
DK172089A DK172089A (da) 1989-10-12
DK175372B1 true DK175372B1 (da) 2004-09-13

Family

ID=22657287

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198901720A DK175372B1 (da) 1988-04-11 1989-04-10 1,3-dioxolanderivater

Country Status (16)

Country Link
EP (1) EP0337713B1 (ja)
JP (1) JP3085675B2 (ja)
KR (1) KR0137023B1 (ja)
AT (1) ATE129247T1 (ja)
AU (1) AU631786B2 (ja)
CA (1) CA1339609C (ja)
DE (1) DE68924549T2 (ja)
DK (1) DK175372B1 (ja)
ES (1) ES2078234T3 (ja)
GR (1) GR3017812T3 (ja)
HK (1) HK5996A (ja)
IE (1) IE71225B1 (ja)
IL (1) IL89921A (ja)
NZ (1) NZ228645A (ja)
OA (1) OA09470A (ja)
ZA (1) ZA892645B (ja)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597824A (en) * 1987-11-03 1997-01-28 Abbott Laboratories Analogs of oxetanyl purines and pyrimidines
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US5684164A (en) * 1988-04-11 1997-11-04 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
IE904378A1 (en) 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5827727A (en) * 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ES2091948T3 (es) * 1990-11-13 1996-11-16 Iaf Biochem Int 1,3-oxatiolanos sustituidos con propiedades antiviricas.
US6228860B1 (en) 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US6369066B1 (en) 1990-11-13 2002-04-09 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes with antiviral properties
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
US6005107A (en) * 1992-12-23 1999-12-21 Biochem Pharma, Inc. Antiviral compounds
GB9226879D0 (en) * 1992-12-23 1993-02-17 Iaf Biochem Int Anti-viral compounds
US6444656B1 (en) 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
JPH09504785A (ja) 1993-09-10 1997-05-13 エモリー、ユニバーシティー 抗ｂ型肝炎ウイルス活性を有するヌクレオシド
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
CA2219132C (en) 1995-06-07 2007-03-06 Emory University Nucleosides with anti-hepatitis b virus activity
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US5792773A (en) * 1996-11-15 1998-08-11 Yale University L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
ES2221164T3 (es) * 1997-03-19 2004-12-16 Emory University Sintesis y actividad de la inmunodeficiencia humana y antivirus de la hepatitis b de nucleosidos de 1,3-oxaselenolano.
DE69933860T2 (de) 1998-02-25 2007-05-31 Emory University 2'-fluoronukleoside
EP1754710A3 (en) 1998-02-25 2007-12-19 Emory University 2'-Fluoroncucleosides
EP1361223B1 (en) 1998-08-12 2005-04-06 Gilead Sciences, Inc. Method of manufacture of 1,3-oxathiolane nucleosides
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
MXPA01004504A (es) 1998-11-05 2005-04-19 Centre Nat Rech Scient Nucleosidos con actividad contra virus de la hepatitis b.
WO2000039143A2 (en) 1998-12-23 2000-07-06 Shire Biochem Inc. Antiviral nucleoside analogues
JP2002540142A (ja) 1999-03-29 2002-11-26 シャイアー・バイオケム・インコーポレイテッド 白血病の処置方法
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
EP1214074B1 (en) * 1999-09-24 2004-06-16 Shire Biochem Inc. Dioxolane nucleoside analogs for the treatment or prevention of viral infection
AU1262001A (en) * 1999-11-04 2001-05-14 Biochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
EP1634888A3 (en) 1999-11-12 2007-11-21 Pharmasset, Inc. Synthesis of 2'-deoxy-L-nucleosides
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
JP2004510832A (ja) * 2000-10-13 2004-04-08 シャイアー・バイオケム・インコーポレイテッド 改善された細胞間送達のためのジオキソランアナログ
AU2002335489B2 (en) 2001-03-01 2008-06-05 Abbott Laboratories Polymorphic and other crystalline forms of cis-FTC
DE10335061B4 (de) * 2003-07-31 2005-11-17 Wacker-Chemie Gmbh Verfahren zur Herstellung von OH-geschützten [4-(2,6-damino-9H-purin-9-yl)-1,3-dioxolan-2-yl]methanol-Derivaten
EP1720840B1 (en) 2004-02-03 2016-02-03 Emory University Methods to manufacture 1,3-dioxolane nucleosides
CN101310021A (zh) 2005-09-26 2008-11-19 法莫赛特股份有限公司 作为抗病毒剂的修饰的4’-核苷
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
PT2041071E (pt) 2006-06-29 2014-09-23 Kinex Pharmaceuticals Llc Composições de biarilo e processos para a regulação de uma cascata de cinases
ES2842334T3 (es) 2007-10-20 2021-07-13 Athenex Inc Composiciones farmacéuticas para modular una cascada de cinasas y métodos de uso de las mismas
US9675632B2 (en) 2014-08-26 2017-06-13 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL76546A (en) * 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
FI87783C (fi) * 1985-05-15 1993-02-25 Wellcome Found Foerfarande foer framstaellning av terapeutiskt anvaendbara 2',3'-dideoxinukleosider

Also Published As

Publication number Publication date
ZA892645B (en) 1989-12-27
OA09470A (en) 1992-11-15
EP0337713A2 (en) 1989-10-18
DE68924549T2 (de) 1996-04-04
AU3264489A (en) 1989-10-12
GR3017812T3 (en) 1996-01-31
KR0137023B1 (ko) 1998-04-25
DK172089D0 (da) 1989-04-10
IL89921A (en) 1993-08-18
ATE129247T1 (de) 1995-11-15
DK172089A (da) 1989-10-12
JP3085675B2 (ja) 2000-09-11
DE68924549D1 (de) 1995-11-23
KR890016046A (ko) 1989-11-28
CA1339609C (en) 1997-12-30
AU631786B2 (en) 1992-12-10
EP0337713B1 (en) 1995-10-18
NZ228645A (en) 1991-09-25
HK5996A (en) 1996-01-19
IL89921A0 (en) 1989-12-15
EP0337713A3 (en) 1990-11-22
ES2078234T3 (es) 1995-12-16
JPH01316375A (ja) 1989-12-21
IE71225B1 (en) 1997-02-12
IE891136L (en) 1989-10-11

Similar Documents

Publication Publication Date Title
DK175372B1 (da) 1,3-dioxolanderivater
US5041449A (en) 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5270315A (en) 4-(purinyl bases)-substituted-1,3-dioxlanes
RU2092485C1 (ru) 1,3-оксатиолан, его геометрические и оптические изомеры, смеси этих изомеров, способ их получения и фармацевтическая композиция, проявляющая антивирусную активность
US6350753B1 (en) 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
EP2322518B1 (en) Method of manufacture of 1,3-dioxolane and 1,3-oxathiolane nucleosides
US20070037975A1 (en) Substituted-1,3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties
WO2008143846A1 (en) Azido purine nucleosides for treatment of viral infections
AU2008201983B2 (en) Method of manufacture of 1,3-oxathiolane nucleosides
BERNARD et al. WITHDRAWN APPLICATION AS PER THE LATEST USPTO WITHDRAWN LIST
IE83856B1 (en) Substituted-1,3-oxathiolanes with antiviral properties

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired